The Exchange had sought clarification from Camlin Fine Sciences Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is enclosed.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The stock exchange asked Camlin Fine Sciences to explain discrepancies found in the XBRL filing of its financial results for the quarter ended 31-March-2025, under Regulation 33 of SEBI's listing rules. The company has now submitted its response to the exchange. No penalty, fine, or enforcement action has been mentioned so far. The issue appears to be limited to a filing-format or data-entry discrepancy rather than a substantive financial irregularity. Shareholders will need to check the company's response for details on what was clarified.
This is a routine compliance clarification and is unlikely to materially affect the stock price, though investors should monitor for any follow-up action from the exchange or any restatement of results.